Amylyx Pharmaceuticals, Inc. AMLX 深 沪
已收盘 08-21 16:00:00 美东时间
38.66
-1.000
-2.52%
华盛通- 最 高41.14
- 今 开39.795
- 成交量 464.28万股
- 最 低 38.35
- 昨 收 39.66
- 总市值 43.08亿
- 52周最高 41.14
- 市盈率 静 --
- 换手率 4.17%
- 52周最低 9.145
- 委 比 60.53%
- 总股本 1.11亿
- 历史最高 41.9297
- 量 比 0.53
- 振 幅 7.03%
- 历史最低 1.575
- 每 手 1
- 风险率 3.70%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股周涨跌榜 | 研发mRNA癌症疫苗获华尔街齐看好！Moderna周涨129%；MSTR周涨28%
研发mRNA癌症疫苗获华尔街齐看好！Moderna周涨129%；AMLX周涨78%，全球首创GLP-1R拮抗剂三期临床试验成功；比特币大幅反弹突破7.8万美元！MSTR周涨28%>>
今天 10:20
美股牛股 | 医药股AMLX飙升63%，全球首创GLP-1R拮抗剂三期临床试验成功；WEAV劲升31%
医药股AMLX飙升63%，全球首创GLP-1R拮抗剂三期临床试验成功；WEAV劲升31%，获私募巨头溢价34%收购；CDNL升逾15%，高管近日增持320万美元股份>>
08-19 16:11
Why Flexsteel Industries Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
Shares of Flexsteel Industries Inc (NASDAQ:FLXS) rose sharply in pre-market trading as the company posted better-than-expected fourth-quarter financial results. The company reported quarterly earnings of $1.33 per share, which beat the analyst consensus estimate of $1.09 per share. The company repor...
08-18 17:01
美股大行评级 | 潜在涨幅455.56%！Cardiol Therapeutics获Canaccord Genuity上调目标价至10美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Cardiol Therapeutics"买入"评级，目标价从8美元升至10美元；B. Riley证券：维持Macrogenics"买入"评级，目标价从9美元升至11美元
08-18 11:39
Amylyx Pharmaceuticals Stock Soars After the Close: Here's Why
Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) shares are trading higher in Monday’s after-hours session after the company scheduled a Phase 3 trial results readout for this week. Amylyx Pharmaceuticals shares are testing new highs. What’s driving AMLX to record levels? Amylyx Pharma Announces Phase 3 LUC...
08-18 04:53
Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $30
Mizuho analyst Graig Suvannavejh maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $24 to $30.
08-17 19:27
美股大行评级 | 潜在涨幅3586.64%！HC Wainwright上调Enlivex目标价至80美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从20美元升至80美元；Canaccord Genuity：维持Pharming Group NV Sponsored ADR"买入"评级，目标价从37美元升至38美元
08-04 11:45
Citigroup Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $26
Citigroup analyst Geoff Meacham maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $20 to $26.
08-04 03:35
美股大行评级 | 伯恩斯坦上调Robinhood目标价从130美元升至160美元；纽约梅隆银行、Datadog、五三银行、旅行者财产险集团获多家机构上调评级
今日重点评级关注：Needham：维持Immuneering"买入"评级，目标价从11美元升至18美元；富瑞：维持塞德斯医疗"买入"评级，目标价从90美元升至100美元
07-21 11:36
Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $24
Mizuho analyst Graig Suvannavejh maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $21 to $24.
07-20 19:34
